Heron Therapeutics Inc ( (HRTX) ) has released its Q3 earnings. Here is a breakdown of the information Heron Therapeutics Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations for acute care and oncology patients. In its latest earnings report for the third quarter of 2025, Heron Therapeutics announced a net revenue of $38.2 million, with a year-to-date revenue of $114.3 million. The company reaffirmed its 2025 net revenue guidance of $153 million to $163 million and adjusted EBITDA of $9.0 million to $13.0 million.
Key highlights from the report include significant revenue growth for Heron’s products, ZYNRELEF and APONVIE. ZYNRELEF’s net revenue increased by 49% compared to the same quarter in 2024, driven by the launch of the Vial Access Needle and enhanced distributor incentives. APONVIE saw an impressive 173% increase in net revenue, supported by a dedicated sales team and increased adoption.
The company’s Acute Care franchise reported a 67.2% year-over-year revenue growth for Q3 2025, indicating strong commercial acceleration. In the oncology segment, CINVANTI’s unit demand and net revenue grew by 6% compared to Q3 2024, maintaining consistent revenue year-over-year. Heron’s cash, cash equivalents, and short-term investments totaled $55.5 million as of September 30, 2025.
Looking ahead, Heron Therapeutics remains focused on driving demand for its products and achieving its financial targets for the year. The company continues to leverage its resources and strategic initiatives to enhance its market presence and deliver value to its stakeholders.